# Clinical Pharmacogenetics Implementation Consortium (CPIC)

> **NIH NIH U24** · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · 2022 · $980,928

## Abstract

ABSTRACT
Pharmacogenomics is often cited as the subset of genomic research that is most amenable to uptake in clinical
medicine. Over the last few years, leading institutions have begun using pharmacogenetic test results to guide
prescribing in some clinical settings, but clinical implementation efforts have documented that rigorous
guidelines are needed to optimally use pharmacogenetic test results. Recognizing this need, we formed the
Clinical Pharmacogenetics Implementation Consortium (CPIC®) in 2009. The goal of CPIC is to provide
resources needed to translate raw genetic test information into prescribing recommendations for specific
gene/drug pairs. This is accomplished through the creation, curation, and dissemination of peer-reviewed,
evidence-based, freely available clinical practice gene/drug guidelines. CPIC is the only NIH-supported group
to focus on translation of pharmacogenomic variation into prescribing actions. We have two specific aims: Aim
1 is to create, curate, and update pharmacogenetic guidelines, and Aim 2 is to work with guideline users and
other public genomic resources to coordinate efforts, disseminate CPIC content, and be responsive to the
needs of the global genomics community. CPIC guidelines are published after standard peer review, and are
simultaneously posted online allowing for real-time updates of guidelines as new information emerges. CPIC
assigns gene/drug pairs to levels of actionability based on standardized criteria. CPIC investigators, working
with internationally recognized experts in each content area, write clinical guidelines for those genes that are
clearly actionable for at least one drug. Guidelines follow best practices, using a standardized format, grading
for levels of evidence and strength of clinical recommendations, and adhering to authorship processes that are
consistent with the Institute of Medicine best practices for clinical guidelines. Guidelines include tables of the
genomic variants that define alleles, assign function to alleles, estimate allele frequency among major ancestry
groups, translate diplotypes into phenotypes, provide prescribing actionability for phenotypes, and include
example clinical decision support language. Considerable outreach efforts by CPIC will continue and have
resulted in broad uptake and endorsement of CPIC guidelines. Content is organized to facilitate usage by the
broad research and clinical community, including related public databases such as PharmGKB, ClinGen,
ClinVar, and PharmVar.

## Key facts

- **NIH application ID:** 10460489
- **Project number:** 5U24HG010135-05
- **Recipient organization:** ST. JUDE CHILDREN'S RESEARCH HOSPITAL
- **Principal Investigator:** Kelly E. Caudle
- **Activity code:** U24 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $980,928
- **Award type:** 5
- **Project period:** 2018-09-20 → 2023-06-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10460489

## Citation

> US National Institutes of Health, RePORTER application 10460489, Clinical Pharmacogenetics Implementation Consortium (CPIC) (5U24HG010135-05). Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/grant/nih/10460489. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*